유전체 소변 검사 시장 보고서(2025년)
Genomic Urine Testing Global Market Report 2025
상품코드 : 1751007
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,661,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,629,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,596,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

유전체 소변 검사 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예측 기간 동안 예상되는 성장은 액체 생검 방법의 채택 증가, 개인 맞춤 의학에 대한 강조 증가, 만성 신장 질환의 유병률 증가, 재택 진단 테스트 솔루션에 대한 관심 증가, 소변 기반 테스트에서 다중 오믹스 접근법의 확대 적용에 기인할 수 있습니다.

만성 신장병의 부담 증가는 향후 몇 년간의 유전체 소변 검사 시장 확대를 촉진할 것으로 예측됩니다. 설탕은 신장의 혈관을 손상시키고 여과 능력을 저하시키기 때문입니다. 이 접근법은 보다 정확한 모니터링을 용이하게 하고 질병의 진행을 지연시킴으로써 환자의 결과를 개선합니다. 예를 들어, 2024년 6월 호주 정부 기관인 호주보건복지연구소는 만성 신장 질환으로 인한 사망률이 2021년 4.2%에서 2022년 6.2%로 증가했다고 보고했습니다.

유전체 소변 검사 업계의 주요 기업은 다양한 질병에 대한 비침습적 진단 검사의 정확성, 감도, 조기 발견 가능성을 향상시키기 위해 차세대 시퀀싱과 같은 혁신적인 진보에 주력하고 있습니다. DNA 단편을 동시에 시퀀싱함으로써 유전 물질의 신속하고 정확하고 대규모 분석을 용이하게 하는 정교한 DNA 시퀀싱 기법입니다. 예를 들어, 2023년 5월, 미국에 본사를 둔 생명공학 회사인 Convergent Genomics Inc.는 게놈 소변 검사 UroAmp를 출시했습니다. 12년 전까지의 조기 발견을 가능하게 합니다. 진단, 치료 계획, 재발 감시를 서포트하는 종합적인 유전자 데이터를 제공해, 세포 진단이나 방광경 검사등의 종래 기술보다 높은 정밀도를 실현합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Genomic urine testing is a non-invasive diagnostic approach that examines genetic material found in urine to identify specific biomarkers associated with various diseases, including cancer, infections, and genetic disorders. This method integrates genomics with advanced molecular techniques to detect mutations, gene expression profiles, or microbial DNA (deoxyribonucleic acid). Its main goal is early disease detection, ongoing monitoring, and the development of personalized treatment strategies for different health conditions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of genomic urine testing include DNA testing, RNA testing, microbial testing, and epigenetic testing. DNA (deoxyribonucleic acid) testing is a scientific technique used to study an individual's genetic makeup to determine biological relationships, verify identity, or uncover inherited health conditions. These tests are distributed through several channels, such as hospital pharmacies, mail-order pharmacies, and specialty pharmacies. Genomic urine tests are applied in areas such as cancer detection, infectious disease diagnosis, genetic disorder screening, and general health assessment. They cater to a broad spectrum of end users, including hospitals and clinics, diagnostic labs, research and academic institutions, and other healthcare providers.

The genomic urine testing market research report is one of a series of new reports from The Business Research Company that provides genomic urine testing market statistics, including the edge artificial intelligence integrated circuits industry global market size, regional shares, competitors with the genomic urine testing market share, detailed genomic urine testing market segments, market trends, and opportunities, and any further data you may need to thrive in the genomic urine testing industry. This genomic urine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The genomic urine testing market size has grown rapidly in recent years. It will grow from$0.90 billion in 2024 to $1.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historical period can be credited to the rising occurrence of urologic cancers, heightened demand for early cancer diagnosis, increased awareness of precision medicine, a growing number of genetic disorder cases, and expanding investments in biomarker research.

The genomic urine testing market size is expected to see rapid growth in the next few years. It will grow to$1.62 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The anticipated growth in the forecast period can be attributed to the rising adoption of liquid biopsy methods, an increasing emphasis on personalized medicine, a growing prevalence of chronic kidney diseases, heightened focus on at-home diagnostic testing solutions, and the expanding application of multi-omics approaches in urine-based testing. Key trends expected during the forecast period include the development of non-invasive diagnostic methods, advancement of high-sensitivity testing panels, integration of machine learning technologies, innovations in urine exosome isolation, and progress in single-cell urine sequencing.

The growing burden of chronic kidney disease is anticipated to drive the expansion of the genomic urine testing market in the coming years. Chronic kidney disease is a condition where the kidneys are damaged and unable to effectively filter blood, leading to an accumulation of waste and fluids in the body. This burden is increasing largely due to the rising prevalence of diabetes, as high blood sugar levels can damage kidney blood vessels, reducing their filtering capability. Genomic urine testing supports the management of chronic kidney disease by enabling early detection of genetic markers, which allows for timely intervention and personalized treatment plans. This approach improves patient outcomes by facilitating more accurate monitoring and slowing disease progression. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that mortality rates due to chronic kidney disease increased from 4.2% in 2021 to 6.2% in 2022. As a result, the escalating burden of chronic kidney disease is contributing to the growth of the genomic urine testing market.

Leading companies in the genomic urine testing industry are concentrating on innovative advancements, such as next-generation sequencing, to improve the precision, sensitivity, and early detection potential of non-invasive diagnostic tests for various illnesses. Next-generation sequencing is a sophisticated DNA sequencing method that facilitates fast, accurate, and large-scale analysis of genetic material by sequencing millions of DNA fragments simultaneously. For instance, in May 2023, Convergent Genomics Inc., a biotechnology company based in the United States, introduced the genomic urine test UroAmp. This test utilizes next-generation DNA sequencing to detect mutations in 60 genes linked to bladder cancer, allowing for early detection up to 12 years before symptoms appear. It offers comprehensive genetic data to support diagnosis, treatment planning, and recurrence monitoring, delivering greater accuracy than conventional techniques such as cytology and cystoscopy.

In September 2024, A. Menarini Diagnostics, an in-vitro diagnostics company headquartered in Italy, formed a partnership with Nucleix Ltd. The collaboration is focused on the commercialization and distribution of Bladder EpiCheck, a non-invasive genomic urine test designed for the early detection and monitoring of bladder and upper tract urothelial cancers throughout Europe. This initiative enhances the availability of advanced cancer diagnostic tools and aligns with clinical guidelines in Europe. Nucleix Ltd. is an Israel-based molecular diagnostics firm that specializes in epigenetic and genomic testing technologies.

Major players in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd.

North America was the largest region in the genomic urine testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in genomic urine testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the genomic urine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The genomic urine testing market includes of revenues earned by entities by providing services such as early disease detection, genetic mutation analysis, cancer screening, infection diagnostics, personalized treatment planning, and monitoring of disease progression through non-invasive urine-based genomic profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Genomic Urine Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on genomic urine testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for genomic urine testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The genomic urine testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Genomic Urine Testing Market Characteristics

3. Genomic Urine Testing Market Trends And Strategies

4. Genomic Urine Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Genomic Urine Testing Growth Analysis And Strategic Analysis Framework

6. Genomic Urine Testing Market Segmentation

7. Genomic Urine Testing Market Regional And Country Analysis

8. Asia-Pacific Genomic Urine Testing Market

9. China Genomic Urine Testing Market

10. India Genomic Urine Testing Market

11. Japan Genomic Urine Testing Market

12. Australia Genomic Urine Testing Market

13. Indonesia Genomic Urine Testing Market

14. South Korea Genomic Urine Testing Market

15. Western Europe Genomic Urine Testing Market

16. UK Genomic Urine Testing Market

17. Germany Genomic Urine Testing Market

18. France Genomic Urine Testing Market

19. Italy Genomic Urine Testing Market

20. Spain Genomic Urine Testing Market

21. Eastern Europe Genomic Urine Testing Market

22. Russia Genomic Urine Testing Market

23. North America Genomic Urine Testing Market

24. USA Genomic Urine Testing Market

25. Canada Genomic Urine Testing Market

26. South America Genomic Urine Testing Market

27. Brazil Genomic Urine Testing Market

28. Middle East Genomic Urine Testing Market

29. Africa Genomic Urine Testing Market

30. Genomic Urine Testing Market Competitive Landscape And Company Profiles

31. Genomic Urine Testing Market Other Major And Innovative Companies

32. Global Genomic Urine Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Genomic Urine Testing Market

34. Recent Developments In The Genomic Urine Testing Market

35. Genomic Urine Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기